Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

141. Bone-density testing interval and transition to osteoporosis in older women. Full Text available with Trip Pro

Bone-density testing interval and transition to osteoporosis in older women. Although bone mineral density (BMD) testing to screen for osteoporosis (BMD T score, -2.50 or lower) is recommended for women 65 years of age or older, there are few data to guide decisions about the interval between BMD tests.We studied 4957 women, 67 years of age or older, with normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.01 to -2.49) and with no history of hip (...) or clinical vertebral fracture or of treatment for osteoporosis, followed prospectively for up to 15 years. The BMD testing interval was defined as the estimated time for 10% of women to make the transition to osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and clinical risk factors. Transitions from normal BMD and from three subgroups of osteopenia (mild, moderate, and advanced) were analyzed with the use of parametric cumulative incidence models

2012 NEJM

142. Osteoporosis: assessing the risk of fragility fracture

Osteoporosis: assessing the risk of fragility fracture Osteoporosis: assessing the risk of Osteoporosis: assessing the risk of fr fragility fr agility fracture acture Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg146 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful (...) in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osteoporosis: assessing the risk of fragility fracture (CG146) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

143. Osteoporosis in Men Full Text available with Trip Pro

Osteoporosis in Men We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation (...) Article navigation 1 June 2012 Article Contents Article Navigation Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline Nelson B. Watts 1Mercy Health Osteoporosis & Bone Health Services (N.B.W.), Cincinnati Ohio 45236 Search for other works by this author on: Robert A. Adler 2McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine (R.A.A.), Richmond, Virginia 23298 Search for other works by this author on: John P. Bilezikian 3Columbia University

2012 The Endocrine Society

144. Osteoporosis

Osteoporosis Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2012 American College of Obstetricians and Gynecologists

145. Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

2012 Evidence-Based Medicine

146. Vitamin D supplementation in patients with osteoporosis

Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vitamin D supplementation in patients with osteoporosis. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions The purpose (...) of vitamin D supplementation is to improve bone and muscle health, thereby reducing the risk of osteoporosis-related fractures. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Bone Densitys; Dietary Supplements; Osteoporosis; Vitamin D; Vitamins Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200

2012 Health Technology Assessment (HTA) Database.

147. How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies

How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies Ferko NC, Borisova N, Airia P, Grima DT, Thompson MF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to explore the effect of varying rebates, co-payments and delivery of drugs (oral or intravenous) on the cost-effectiveness of osteoporosis treatment, for managed care organisations. The authors concluded that the cost-effectiveness of the drugs varied considerably when these factors were

2012 NHS Economic Evaluation Database.

148. Fracture risk and zoledronic acid therapy in men with osteoporosis. Full Text available with Trip Pro

Fracture risk and zoledronic acid therapy in men with osteoporosis. Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion (...) <0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%).Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

2012 NEJM Controlled trial quality: predicted high

149. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of secondary plus tertiary prevention of osteoporosis by identifying post-menopausal women who were at increased risk of fractures, compared with tertiary prevention alone. The authors concluded that both prevention strategies were cost-effective compared with no prevention. Secondary plus tertiary prevention was more effective and more

2012 NHS Economic Evaluation Database.

150. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

151. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

152. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

153. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Full Text available with Trip Pro

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. The best strategies to screen postmenopausal women for osteoporosis are not clear.To identify the cost-effectiveness of various screening strategies.Individual-level state-transition cost-effectiveness model.Published literature.U.S. women aged 55 years or older.Lifetime.Payer.Screening strategies composed of alternative tests (central dual-energy x-ray absorptiometry [DXA], calcaneal quantitative (...) ultrasonography [QUS], and the Simple Calculated Osteoporosis Risk Estimation [SCORE] tool) initiation ages, treatment thresholds, and rescreening intervals. Oral bisphosphonate treatment was assumed, with a base-case adherence rate of 50% and a 5-year on/off treatment pattern.Incremental cost-effectiveness ratios (2010 U.S. dollars per quality-adjusted life-year [QALY] gained).At all evaluated ages, screening was superior to not screening. In general, quality-adjusted life-days gained with screening tended

2011 Annals of Internal Medicine

154. Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines

Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Canadian Agency for Drugs (...) and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH

2011 Health Technology Assessment (HTA) Database.

155. Zoledronic acid - Osteoporosis (postmenopausal women)

Zoledronic acid - Osteoporosis (postmenopausal women) Common Drug Review CDEC Meeting – October 19, 2011 Page 1 of 4 Notice of CDEC Final Recommendation – November 16, 2011 © 2011 CADTH CDEC FINAL RECOMMENDATION ZOLEDRONIC ACID – REQUEST FOR ADVICE (Aclasta – Novartis Pharmaceuticals Inc.) Indication: Osteoporosis (postmenopausal women) Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that zoledronic acid be listed for women with postmenopausal osteoporosis who would (...) alendronate. 2. The cost of zoledronic acid is approximately five times that of generic alendronate. 3. The Committee recognized that there may be a small proportion of women who are otherwise eligible for jurisdictional funding of oral bisphosphonates but who are unable to take oral bisphosphonates and who may benefit from annual intravenous (IV) bisphosphonate therapy. Background: Zoledronic acid (marketed as Aclasta) has a Health Canada indication for: • Treatment of osteoporosis in postmenopausal

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

156. Whole-body vibration therapy for osteoporosis: state of the science. (Abstract)

Whole-body vibration therapy for osteoporosis: state of the science. Clinical guidelines for osteoporosis recommend dietary and pharmacologic interventions and weight-bearing exercise to prevent bone fractures. These interventions sometimes have low adherence and can cause adverse effects. A proposed alternative or adjunctive treatment is whole-body vibration therapy (WBV), in which energy produced by a forced oscillation is transferred to an individual from a mechanical vibration platform (...) . Whole-body vibration platforms are not approved by the U.S. Food and Drug Administration for medical purposes. This review provides a broad overview of important issues related to WBV therapy for prevention and treatment of osteoporosis. Relying on key informants and a search of the gray and published literature from January 2000 to August 2011, the investigators found that the designs of WBV platforms and protocols for their use vary widely. The optimal target population for the therapy

2011 Annals of Internal Medicine

157. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis

The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

158. The societal burden of poor persistence to treatment of osteoporosis in Sweden

The societal burden of poor persistence to treatment of osteoporosis in Sweden The societal burden of poor persistence to treatment of osteoporosis in Sweden The societal burden of poor persistence to treatment of osteoporosis in Sweden Landfeldt E, Lundkvist J, Strom O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the societal burden of poor maintenance of prescribed treatments for osteoporosis and the cost-effectiveness of improving adherence. The authors concluded that poor persistence with the treatment of osteoporosis was an important and costly health burden, and it should be considered when evaluating interventions. Some key assumptions were made, but the methods were valid and the authors

2011 NHS Economic Evaluation Database.

159. Osteoporosis. (Abstract)

Osteoporosis. 21727287 2011 09 06 2013 06 25 1539-3704 155 1 2011 Jul 05 Annals of internal medicine Ann. Intern. Med. In the clinic. Osteoporosis. ITC1-1-15; quiz ITC1-16 10.7326/0003-4819-155-1-201107050-01001 Lewiecki E Michael EM eng Journal Article Review United States Ann Intern Med 0372351 0003-4819 0 Bone Density Conservation Agents 0 Calcium Compounds 1406-16-2 Vitamin D AIM IM Bone Density Conservation Agents therapeutic use Calcium Compounds therapeutic use Dietary Supplements (...) Exercise Female Humans Male Osteoporosis complications diagnosis prevention & control therapy Osteoporotic Fractures etiology Patient Education as Topic Risk Factors Vitamin D therapeutic use 2011 7 6 6 0 2011 7 6 6 0 2011 9 7 6 0 ppublish 21727287 155/1/ITC1-1 10.7326/0003-4819-155-1-201107050-01001

2011 Annals of Internal Medicine

160. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Full Text available with Trip Pro

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to estimate the cost-effectiveness of denosumab compared with various oral treatments for osteoporosis in postmenopausal women. The authors concluded that denosumab was a cost-effective alternative to oral osteoporosis treatments, particularly for patients at high risk of fracture, who were not expected to fully adhere to oral treatment. On the whole

2011 NHS Economic Evaluation Database.